<DOC>
	<DOC>NCT00189826</DOC>
	<brief_summary>To evaluate and to compare efficacy and safety of a dual regimen with oral modified release tacrolimus FK506E (MR4) / steroids versus a dual regimen with oral tacrolimus FK506 / steroids in patients undergoing primary liver transplantation. It shall be demonstrated that FK506E (MR4) is non-inferior to FK506 with regards to the primary endpoint.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Liver Transplantation.</brief_title>
	<detailed_description>A multicentre, 1:1 randomised, double blind, double dummy, two arm parallel group phase III study comparing a dual modified release FK506E (MR4) / steroid regimen with a standard tacrolimus FK506 / steroid regimen.</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients receiving a primary, split liver or a whole liver graft from a cadaveric donor with compatible ABO blood type. Patients receiving a multiorgan transplant or having previously received an organ transplant (including liver retransplantation). Patients with severe diarrhoea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus. Patients with serum creatinine &gt; 200 Âµmol/l..</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Liver transplantation</keyword>
</DOC>